Pancreatic Cancer Research

ResearcherKagawa UniversityActive in the last 2 years

Tsutomu Masaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8425-0685; OpenAlex author ID A5017931660, A5091806604. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 5 papers · 2021: none · 2022: 6 papers · 2023: 2 papers · 2024: 1 paper

Papers 20

  1. Serum Carbohydrate Antigen 19-9 and Metabolite Hypotaurine Are Predictive Markers for Early Recurrence of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002304↗
  2. P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with … Co-author DOI 10.1002/jhbp.1286↗
  3. Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adeno… Co-author DOI 10.1016/j.hpb.2022.10.004↗
  4. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiothe… Co-author DOI 10.1002/jso.26854↗
  5. Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer. Co-author DOI 10.1093/jjco/hyac074↗
  6. Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002011↗
  7. Role of Short-Term Neoadjuvant Chemoradiotherapy for Potentially Resectable Pancreatic Cancer. Co-author DOI 10.1177/0003134821998671↗
  8. Effect of Aspirin on G0/G1 Cell Cycle Arrest and microRNA Signatures in Pancreatic Adenocarcinoma Cells. Last author DOI 10.21873/anticanres.15900↗
  9. MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells. Last author DOI 10.4103/jcrt.jcrt_104_20↗
  10. Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H. Co-author DOI 10.1038/s42003-020-01434-x↗
  11. Antiproliferative Effects of Monoclonal Antibodies against (Pro)Renin Receptor in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-19-0228↗
  12. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable p… Co-author DOI 10.1186/s12876-020-01566-8↗
  13. Is surgery after neoadjuvant chemoradiotherapy feasible for elderly patients with resectable or borderline resectable pancreatic ductal adenocarcinoma? Co-author DOI 10.21203/rs.2.21112/v1↗
  14. The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells. Last author DOI 10.21873/invivo.12155↗
  15. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvan… Co-author DOI 10.1186/s12893-019-0644-z↗
  16. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyy033↗
  17. MicroRNA profiles during galectin-9-induced apoptosis of pancreatic cancer cells. Last author DOI 10.3892/ol.2017.7316↗
  18. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic … Co-author DOI 10.1245/s10434-017-5921-4↗
  19. The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effec… Last author DOI 10.3892/or.2015.4496↗
  20. (Pro)renin receptor is crucial for Wnt/β-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep08854↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keiichi Okano · 14 shared papers, 2017–2024 · strength 1.72
  2. Hironobu Suto · 12 shared papers, 2017–2024 · strength 1.54
  3. Minoru Oshima · 12 shared papers, 2017–2024 · strength 1.54
  4. Yasuyuki Suzuki · 13 shared papers, 2015–2023 · strength 1.47
  5. Toru Shibata · 7 shared papers, 2017–2023 · strength 0.83
  6. Shigeo Takahashi · 6 shared papers, 2017–2023 · strength 0.73
  7. Mina Nagao · 3 shared papers, 2018–2024 · strength 0.37
  8. Ayaka Shimomura · 2 shared papers, 2022–2024 · strength 0.29
  9. Yukiko Wada · 2 shared papers, 2022–2024 · strength 0.29
  10. Akira Nishiyama · 3 shared papers, 2015–2020 · strength 0.23
  11. Yuki Shibayama · 3 shared papers, 2015–2020 · strength 0.23
  12. Akihito Tsuji · 2 shared papers, 2018–2022 · strength 0.21
  13. Kiyohito Kato · 3 shared papers, 2016–2020 · strength 0.21
  14. Daisuke Namima · 2 shared papers, 2020–2022 · strength 0.21
  15. Asadur Rahman · 2 shared papers, 2020 · strength 0.18
  16. Yoshimi Yamana · 1 shared paper, 2022 · strength 0.14
  17. Shinichi Yachida · 2 shared papers, 2015–2020 · strength 0.13
  18. Ryota Nakabayashi · 1 shared paper, 2022 · strength 0.12
  19. Toru Furukawa · 1 shared paper, 2020 · strength 0.09
  20. Ryoichi Okura · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.